Transcend Capital Advisors LLC Sells 458 Shares of Novo Nordisk A/S (NYSE:NVO)

Transcend Capital Advisors LLC decreased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 11.3% during the fourth quarter, HoldingsChannel reports. The firm owned 3,602 shares of the company’s stock after selling 458 shares during the quarter. Transcend Capital Advisors LLC’s holdings in Novo Nordisk A/S were worth $373,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Westside Investment Management Inc. grew its holdings in Novo Nordisk A/S by 83.3% in the third quarter. Westside Investment Management Inc. now owns 1,428 shares of the company’s stock worth $130,000 after purchasing an additional 649 shares during the period. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD bought a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at $2,408,000. Lazard Asset Management LLC boosted its stake in shares of Novo Nordisk A/S by 182.2% in the 3rd quarter. Lazard Asset Management LLC now owns 1,494,214 shares of the company’s stock worth $135,883,000 after buying an additional 964,640 shares during the last quarter. CENTRAL TRUST Co grew its holdings in shares of Novo Nordisk A/S by 111.6% in the third quarter. CENTRAL TRUST Co now owns 6,004 shares of the company’s stock worth $546,000 after acquiring an additional 3,166 shares during the period. Finally, Ieq Capital LLC increased its position in Novo Nordisk A/S by 136.6% during the third quarter. Ieq Capital LLC now owns 27,474 shares of the company’s stock valued at $2,498,000 after acquiring an additional 15,860 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO opened at $126.92 on Tuesday. The company has a market cap of $569.56 billion, a P/E ratio of 46.92, a P/E/G ratio of 2.12 and a beta of 0.41. Novo Nordisk A/S has a 52-week low of $75.56 and a 52-week high of $138.28. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82. The firm’s fifty day moving average is $126.92 and its two-hundred day moving average is $112.40.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. The company had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. As a group, analysts anticipate that Novo Nordisk A/S will post 3.32 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were issued a $0.664 dividend. The ex-dividend date of this dividend was Friday, March 22nd. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. This represents a dividend yield of 0.9%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 49.17%.

Analyst Ratings Changes

Several equities research analysts have recently commented on NVO shares. UBS Group initiated coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a “neutral” rating for the company. BMO Capital Markets began coverage on shares of Novo Nordisk A/S in a research report on Friday, April 12th. They set an “outperform” rating and a $163.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Finally, Morgan Stanley initiated coverage on Novo Nordisk A/S in a report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target for the company. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.